New Hampshire to offer Gardasil vaccinations free to all girls

Share this article:
New Hampshire health officials plan to offer Merck’s Gardasil human papillomavirus (HPV) vaccine free to all girls to help protect them against cervical cancer. “New Hampshire will be the first state in the country to offer the vaccine in its universal children’s (vaccine) program,” New Hampshire Health and Human Services Commissioner John Stephen told the Associated Press. The New Hampshire Vaccines for Children program is funded by the federal government and private insurers and offers “no-cost” immunizations to children through age 18. The program also pays to vaccinate children against other diseases, such as hepatits A and B, polio and measles. A total of $4.8 million has been budgeted for the vaccine next year, reports said. New Hampshire officials gave doctors the OK to begin ordering the vaccine last Friday, for shipment in January. State officials hope 17,000 young women—25% of those eligible—will come forward for the vaccinations during 2007. Gardasil was approved by the FDA in June for females nine to 26 years old. The vaccine helps protect against four types of HPV responsible for most strains of the disease. A Centers for Disease Control and Prevention panel recommended Gardasil for use in girls 11 and 12, and down to nine per a physician’s discretion, and for all those not vaccinated from 13 to 26.
Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union